The Arising · Intelligence

OCTOBER 17, 2026 BioAge Labs and AI drug discovery company Deep Origin have launched a multi-target collaboration that already reached its first milestone: Deep Origin's software produced lab-confirmed drug hits against a new BioAge target in under three months. Financial terms were not disclosed beyond Deep Origin's eligibility for milestone payments. The useful moment in AI-assisted discovery is when a prediction survives contact with an experiment. The companies report an early example here, with the much longer development process still ahead. The companies announced the collaboration on October 14, 2026, according to Contract Pharma. BioAge is a clinical-stage company that develops treatments for cardiometabolic diseases by targeting the biology of human aging. Deep Origin supplies computational drug discovery. The first milestone is concrete. Deep Origin's platform delivered several structurally distinct small-molecule hits against the target. BioAge's wet lab then validated them. BioAge is now moving that target into hit-to-lead optimization, the stage where chemists refine early hits into more drug-like molecules. According to Contract Pharma, the collaboration relies on hybrid AI and physics-based models, which lets the companies focus on novel targets, meaning those with little known chemistry to start from. Deep Origin CEO Michael Antonov described the fit this way: "BioAge finds its targets in human data, from people followed for decades." He said many of those targets are novel, with little known chemistry, which is the problem Deep Origin's virtual screening was built to address. He also said BioAge set a high bar for the molecules its chemists would take forward. BioAge CEO Kristen Fortney said, "AI can help shorten the path from human biology to new medicines." She said the collaboration showed potential to speed early small-molecule discovery, and that BioAge looks forward to extending the work to additional targets. On the business side, Deep Origin is eligible for milestone payments based on the success of the collaboration. Contract Pharma did not report an upfront payment, a total deal value or how many targets are planned. Because those terms were not disclosed, readers should not assume there are no upfront or access fees, and the size of the commitment is hard to judge. For the market, the deal is a modest but useful data point. Many companies now sell AI-driven discovery, and the open question is whether it delivers usable starting molecules on hard, unprecedented targets. Milestone payments linked to the collaboration's success may suggest some confidence on both sides, but that is our reading, and the source does not say how the payments are set or what else Deep Origin is paid. Some caution applies. Hits are an early step. The announcement does not say whether any molecule will become a clinical candidate, and the timeline claim comes from the companies themselves. Early discovery speed matters only if later stages also succeed. WHAT TO WATCH NEXT Whether BioAge names additional targets under the agreement, and whether the first target produces optimized lead compounds from the hit-to-lead work. The next milestones will show whether the initial hits can become viable leads. Faster learning is valuable when each step produces evidence the next can use. Source: Contract Pharma ---

OCTOBER 16, 2026 The ovary does not go quiet after menopause. A new study in Aging Cell finds that its protein makeup keeps shifting for decades, toward more inflammation and tissue remodeling. A reproductive milestone does not bring an organ's biology to a stop. Looking at postmenopausal ovarian tissue opens questions about changes that continue across later decades. The work is an observational laboratory study of human tissue. Researchers at Northwestern University and the Buck Institute for Research on Aging analyzed healthy, non-pathological ovaries from 28 postmenopausal women aged 50 to 75. Each ovary was measured once, so the study compares different women at different ages. It does not follow the same women over time. The team used mass spectrometry, a method that identifies and measures proteins in a tissue sample. They quantified 5,812 protein groups. The women were split into three age groups: 50-59, 60-69 and 70 and older. Protein levels moved progressively with age. In all, 117 proteins differed significantly between the oldest group and the youngest. According to the study, the pattern in women in their 50s pointed to RNA and gene-regulation functions. In women 70 and older, it pointed to metabolic, trafficking, and innate immune and complement pathways. The complement system is part of the body's immune defenses. Using several statistical approaches, the authors identified a set of 26 proteins that tracked with age consistently. They named it the Buck Postmenopausal Ovary Molecular Signature, or BuckPOMS. The study says it captures steady remodeling of the extracellular matrix, the scaffolding around cells. It also captures more inflammatory signaling and a loss of structural and keratin-associated proteins. Two of these proteins, WNT4 and fibromodulin, were checked directly in tissue sections by immunohistochemistry, a staining technique. The study also reports higher levels of inflammatory and matrisome pathways, and more damage-associated secreted factors, decades after menopause. The matrisome is the collection of proteins that make up that surrounding scaffold. The authors conclude that the postmenopausal ovary is not inert. They describe active, continuous molecular remodeling with potential relevance to tissue signaling and women's health. FOR YOU What does this mean for personal health? The study shows that the tissue changes. It does not show what those changes do. It did not measure bone, brain or other organs, and it did not track health outcomes. Whether the ovary's changes affect whole-body aging remains an open question. The same limit applies to surgery decisions. The study did not test removing ovaries, and it does not say whether healthy ovaries should stay or go. According to Northwestern's news release, the findings raise new questions about whether otherwise healthy ovaries should one day be removed. That goes further than the data. Anyone weighing this choice should rely on their own doctor and current guidelines. The release also describes a link to ovarian cancer. This detail comes from the press coverage, not from the abstract of the study. The release says the tissue was cancer-free, and that some proteins previously associated with ovarian cancer were more abundant in older ovaries, most strongly in women in their 60s. It adds that this does not mean the ovaries were cancerous or precancerous. Francesca Duncan, a co-corresponding author, told Northwestern: "Is the ovary the canary in the coal mine in women?" She also said it is not yet known whether the changes are beneficial or harmful as women age. The sample is small, and each woman was sampled once. The findings show associations between age and protein levels, not cause and effect. The next step is research that follows these changes over time and tests whether they affect health elsewhere in the body. The next work can investigate what those changes do. There is considerable room to learn about a period of women's health that extends well beyond the final menstrual period. Sources: Aging Cell (2026), Northwestern University (study published in Aging Cell) Aging Cell (2026),: https://doi.org/10.1111/acel.70714 Northwestern University (study published in Aging Cell): https://news.northwestern.edu/stories/2026/10/the-ovary-doesnt-retire-after-menopause?fj=1 ---

OCTOBER 15, 2026 Aging muscle has a puzzle at its core: as mitochondria, the cell's energy units, work less well, muscle shifts toward fibers that rely on them more. A new study in Nature Aging suggests a single fat in the mitochondrial membrane, called cardiolipin, may explain why. The ability to move depends on events far below the scale of a muscle. Research on cardiolipin follows one of those connections, from a mitochondrial membrane toward the changing performance of aging tissue. The evidence comes mainly from mice, with some work in human muscle. It is a peer-reviewed paper published in 2026 by a large team, led by Fabian Finger and Zachary Gerhart-Hines at the University of Copenhagen, according to Earth.com's coverage. We could review only the abstract, which does not give the number of animals or people studied. Anything beyond the abstract below is attributed to Earth.com. According to the abstract, aging brings two changes that seem to conflict. Mitochondrial function in skeletal muscle declines. Yet muscle composition shifts toward fibers rich in mitochondria. The authors report that cardiolipin links the two. Its levels fall in aging mouse and human muscle. To test cause, the researchers lowered cardiolipin in young mice. They deleted a gene called Crls1, which makes an enzyme needed to build the fat, only in muscle and only on cue. This reproduced key hallmarks of aging, including a shift from glycolytic fibers to oxidative ones. Glycolytic fibers burn sugar quickly. Earth.com describes them as the fast, powerful fibers. The abstract also describes how the shift happens. Mitochondria send a signal to the cell nucleus through a protein called estrogen-related receptor γ. That signal promotes sugar uptake that is sensitive to reactive oxygen species, which are damaging byproducts of energy production. It also reroutes sugar to support the cell's antioxidant defenses. Some of the damage was also reversible in the mice. When the authors restored Crls1 in adult mice that had lost it, cardiolipin levels returned, muscle atrophy began to reverse and premature death was fully rescued, according to the abstract. The abstract does not say whether the fiber-type shift itself reversed. Earth.com reports a result that the abstract does not describe. Cardiolipin-depleted mice given the antioxidant N-acetylcysteine for eight weeks ended up with smaller muscles, not healthier ones. Finger told Earth.com: "The fiber switch is not the muscle failing, but the muscle trading power for protection." Earth.com says these groups were small, with three to six mice each. That is the basis for the question many readers will ask about antioxidant pills. The study does not answer it. The mice had been engineered to lack cardiolipin, and the study did not test supplements in older people. Earth.com also notes that the human data were limited to stored muscle samples from nine men, which showed only that cardiolipin was lower with age. Readers should not start or stop any supplement or medication without talking to their clinician. The same goes for exercise. The abstract does not mention training, so we cannot say whether building power slows this fiber shift. What the study does suggest is that the loss of powerful fibers may have a specific biological cause. That makes the cause a possible target for future treatments. It is not yet a guide to what anyone should do. Earth.com reports that the authors' next step is to raise cardiolipin in naturally old mice and see whether that protects their muscles. That result will show whether this pathway matters beyond a model of early muscle aging. The appeal is in the connection between scales. Establishing whether the mechanism can be safely influenced in people would bring that connection closer to clinical use. Sources: Nature aging (2026), Earth.com (reporting on a University of Copenhagen study in Nature Aging) Nature aging (2026): https://doi.org/10.1038/s43587-026-01227-7 Earth.com (reporting on a University of Copenhagen study in Nature Aging): https://www.earth.com/science/aging-muscles-may-be-sacrificing-strength-to-protect-themselves/ ---